Tempus
PROVIDERS
LIFE SCIENCES
PATIENTS
OUR PLATFORM
ORDER A TEST
Log In
Contact Us
Menu
Tempus
ORDER A TEST
Log In
Contact Us
Providers
Oncology
Neurology & Psychiatry
Infectious Disease
Cardiology
Academic & Research
EMR Integration
Life Sciences
Sequencing
Companion Diagnostics
Clinical Trial Solutions
Data Collaborations
AI Applications
Biological Modeling
Patients
Oncology Patients
Neurology Patients
Infectious Disease Patients
Our Platform
Genomic Profiling
Clinical Trial Matching
Companion Diagnostics
Multi-Omics
Tempus ONE
Infectious Disease
About Us
Our Team
Careers
Culture
Resources
Publications
News
Blog
Resources
Publications
Keyword search
Filter By
Oncology
Infectious Disease
Cardiology
Neuro/Psych
05/20/2021
Oncology
Primary Pancreatic Adenocarcinoma (PPDA) and Metastatic Pancreatic Adenocarcinoma (MPDA): Are They Genomically Distinct?
05/20/2021
Oncology
Expanding the Molecular Taxonomy of NUT Midline Carcinomas With Multiomic Analyses
05/20/2021
Oncology
Leveraging Machine Learning Technology to Efficiently Identify and Match Patients for Precision Oncology Clinical Trials
05/20/2021
Oncology
Comprehensive Genomic and Transcriptomic Profiling of Pediatric Malignancies Using the Tempus xT Next-Generation Sequencing Assay to Identify Clinically Meaningful Alterations
05/20/2021
Oncology
Multimodal Profiling of Biliary Tract Cancers to Detect Potentially Actionable Biomarkers and Differences in Immune Signatures Between Subtypes
05/20/2021
Oncology
A Review of Evidence Supporting NCCN Category 2B Off-label Recommendations for Determination of Medicare Reimbursement Eligibility
05/20/2021
Oncology
Rate of Incidental Germline Findings Detected by Tumor-Normal Matched Sequencing in Cancer Types Lacking Hereditary Cancer Testing Guidelines
05/20/2021
Oncology
The TIME Trial Network to Facilitate Rapid Clinical Trial Activation, Patient Screening, and Enrollment in Molecularly Targeted Trials
05/20/2021
Oncology
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology (IO) Biomarkers
04/14/2021
Oncology
Novel Targetable FGFR2 and FGFR3 Alterations in Glioblastoma Associate With Aggressive Phenotype and Distinct Gene Expression Programs
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21